News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

Opinion|Videos|September 11, 2024

Central Precocious Puberty in Male Patients

Author(s)Karen O. Klein, MD, Jill Samis, MD , Aviva B. Sopher, MD, MS

The panel examines potential long-term effects of central precocious puberty treatment on bone density and spermatogenesis in male patients.

Episodes in this series

3 KOLs are featured in this series.

EP. 1 Overview Of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 2 Diagnosis of Central Precocious Puberty and its Psychosocial Impact

3 KOLs are featured in this series.

EP. 3 Early Diagnosis and Treatment for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 4 Treatment Options for Central Precocious Puberty

3 KOLs are featured in this series.

EP. 5 Safety and Efficacy of GnRHa Treatments in Central Precocious Puberty

3 KOLs are featured in this series.

EP. 6 Individualized Management of Central Precocious Puberty

3 KOLs are featured in this series.

EP. 7 Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions

3 KOLs are featured in this series.

EP. 8 Central Precocious Puberty in Male Patients

3 KOLs are featured in this series.

EP. 9 Recommendations and Outlook for Central Precocious Puberty

Video content above is prompted by the following:

How do you address bone density concerns and spermatogenesis in a male patient with CPP?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Latest CME

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

In-Person + Virtual Event

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

January 23, 2026

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA approves gepotidacin as oral treatment for urogenital gonorrhea

FDA approves powder formulation of trofinetide for Rett syndrome

FDA approves berotralstat for patients aged 2 to 11 years with hereditary angioedema

Reports: FDA launching safety review of nirsevimab and clesrovimab for RSV

FDA approves Nuzolvence (zoliflodacin) for treatment of uncomplicated urogenital gonorrhea in 12 years and up

© 2025 MJH Life Sciences^®

All rights reserved.